Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 107 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Chugai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Chugai Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Chugai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Chugai Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Chugai Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Chugai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Chugai Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Chugai Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Chugai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chugai Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Chugai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co., Ltd. Snapshot 7
Chugai Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Chugai Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Chugai Pharmaceutical Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance 18
Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Chugai Pharmaceutical Co., Ltd. - Drug Profiles 23
alectinib 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
tofogliflozin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
vemurafenib 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
bevacizumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
hyaluronate sodium 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ibandronate sodium 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
lebrikizumab 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
obinutuzumab 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pertuzumab 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RG-7446 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SA-237 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
trastuzumab emtansine 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CIM-331 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
RG-7686 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ACE-910 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
gantenerumab 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RG-7167 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
RG-7304 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
2-152a Monoclonal Antibody 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Antibody Targeting Cancer Stem Cells 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CH-5036249 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CH-5164840 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CH-5449302 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CH-5451098 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cVE-199 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
maxacalcitol 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NA-255 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules as Dual RAF/MEK Inhibitors for Cancer 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
UR-1102 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis 70
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target 70
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 72
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 73
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 74
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates 76
Chugai Pharmaceutical Co., Ltd. - Dormant Projects 98
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 99
Discontinued Pipeline Product Profiles 99
NT-675 99
onartuzumab 99
orlistat 100
PA-799 100
parsatuzumab 100
tocilizumab 100
Chugai Pharmaceutical Co., Ltd. - Company Statement 101
Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries 103
Head Office 103
Other Locations & Subsidiaries 103
Chugai Pharmaceutical Co., Ltd. - Key Manufacturing Facilities 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107

List of Tables
Chugai Pharmaceutical Co., Ltd., Key Information 7
Chugai Pharmaceutical Co., Ltd., Key Facts 7
Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 9
Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 11
Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 12
Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 13
Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2014 16
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 17
Chugai Pharmaceutical Co., Ltd. - Pre-Registration, 2014 18
Chugai Pharmaceutical Co., Ltd. - Phase III, 2014 19
Chugai Pharmaceutical Co., Ltd. - Phase II, 2014 20
Chugai Pharmaceutical Co., Ltd. - Phase I, 2014 21
Chugai Pharmaceutical Co., Ltd. - Preclinical, 2014 22
Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 71
Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 72
Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 73
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 75
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 76
Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 98
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 99
Chugai Pharmaceutical Co., Ltd., Other Locations 103
Chugai Pharmaceutical Co., Ltd., Subsidiaries 104
Chugai Pharmaceutical Co., Ltd., Key Manufacturing Facilities 105